drugset
Drugs / TS-172
last change May 2026 re-read 2 minutes ago

TS-172

Developed for
hyperphosphatemia
Investigated by
Taisho Pharmaceutical Co., Ltd.

Trials 14 · a red edge is where a trial was stopped

today NCT07548853 · Ph 3 NCT07548840 · Ph 3 NCT07285291 · Ph 3 NCT07231029 · Ph 1 NCT07285304 · Ph 3 NCT07084961 · Ph 1 NCT06849778 · Ph 1 NCT06837142 · Ph 1 NCT06837155 · Ph 1 NCT06745531 · Ph 3 NCT06745518 · Ph 2 NCT06596356 · Ph 1 NCT05699239 · Ph 2 NCT04979572 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT07231029 Dec 2025 → Oct 2026 expected — Taisho Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT07084961 Aug → Sep 2025 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06849778 Mar → Apr 2025 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06837142 Mar → Apr 2025 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06837155 Mar → May 2025 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06596356 Sep → Oct 2024 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT04979572 Aug 2021 → Jan 2022 — Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT06745518 Jan → Jul 2025 hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 2 NCT05699239 Feb → Dec 2023 hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 35 trials
Phase 3 NCT07548853 May 2026 → May 2027 expected hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07548840 May → Nov 2026 expected hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07285291 Jan → Dec 2026 expected hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07285304 Dec 2025 → Jul 2027 expected hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06745531 Jan → Oct 2025 hyperphosphatemia Taisho Pharmaceutical Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as TS-172 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596356 ↗
13

NCT06837142 ↗

NCT07084961 ↗

NCT07231029 ↗

NCT07285291 ↗

NCT06837155 ↗

NCT07285304 ↗

NCT06745531 ↗

NCT07548853 ↗

NCT06745518 ↗

NCT04979572 ↗

NCT07548840 ↗

NCT06849778 ↗

NCT05699239 ↗
Route Oral “oral administration” NCT05699239 ↗